10 20 30 40 50 60 70 80 1H27 - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER HYDROLASE/HYDROLASE INHIBITOR 31-JUL-02 1H27
TITLE CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM TITLE 2 P27
COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: CYCLIN-DEPENDENT KINASE 2, P33 PROTEIN KINASE; COMPND 5 EC: 2.7.1.-; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: PHOSPHORYLATED ON THR160; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: CYCLIN A2; COMPND 10 CHAIN: B, D; COMPND 11 FRAGMENT: CYCLIN FOLD, RESIDUES 175-432; COMPND 12 SYNONYM: CYCLIN A; COMPND 13 ENGINEERED: YES; COMPND 14 MOL_ID: 3; COMPND 15 MOLECULE: CYCLIN-DEPENDENT KINASE INHIBITOR 1B; COMPND 16 CHAIN: E; COMPND 17 FRAGMENT: RESIDUES 25-35; COMPND 18 SYNONYM: CYCLIN-DEPENDENT KINASE INHIBITOR P27, P27KIP1; COMPND 19 ENGINEERED: YES
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: B834; SOURCE 8 EXPRESSION_SYSTEM_PLASMID: PGEX; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 15 EXPRESSION_SYSTEM_STRAIN: B834; SOURCE 16 EXPRESSION_SYSTEM_PLASMID: PET21D; SOURCE 17 MOL_ID: 3; SOURCE 18 SYNTHETIC: YES; SOURCE 19 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 20 ORGANISM_COMMON: HUMAN; SOURCE 21 ORGANISM_TAXID: 9606
KEYWDS CELL CYCLE, PROTEIN KINASE, CYCLIN, CDK2, RECRUITMENT, PEPTIDE KEYWDS 2 SPECIFICITY, SERINE/THREONINE-PROTEIN KINASE, ATP-BINDING, CELL KEYWDS 3 DIVISION, MITOSIS, PHOSPHORYLATION, HYDROLASE-HYDROLASE INHIBITOR KEYWDS 4 COMPLEX
EXPDTA X-RAY DIFFRACTION
AUTHOR I.TEWS,K.Y.CHENG,E.D.LOWE,M.E.M.NOBLE,N.R.BROWN,S.GUL,S.GAMBLIN, AUTHOR 2 L.N.JOHNSON
REVDAT 4 13-JUL-11 1H27 1 VERSN REVDAT 3 24-FEB-09 1H27 1 VERSN REVDAT 2 24-JUN-03 1H27 1 REMARK ATOM REVDAT 1 01-FEB-03 1H27 0
JRNL AUTH E.D.LOWE,I.TEWS,K.Y.CHENG,N.R.BROWN,S.GUL,M.E.M.NOBLE, JRNL AUTH 2 S.GAMBLIN,L.N.JOHNSON JRNL TITL SPECIFICITY DETERMINANTS OF RECRUITMENT PEPTIDES BOUND TO JRNL TITL 2 PHOSPHO-CDK2/CYCLIN A JRNL REF BIOCHEMISTRY V. 41 15625 2002 JRNL REFN ISSN 0006-2960 JRNL PMID 12501191 JRNL DOI 10.1021/BI0268910
REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH N.R.BROWN,M.E.M.NOBLE,J.A.ENDICOTT,L.N.JOHNSON REMARK 1 TITL THE STRUCTURAL BASIS FOR SPECIFICITY OF SUBSTRATE AND REMARK 1 TITL 2 RECRUITMENT PEPTIDES FOR CYCLIN-DEPENDANT KINASES REMARK 1 REF NAT.CELL BIOL. V. 1 438 1999 REMARK 1 REFN ISSN 1465-7392 REMARK 1 PMID 10559988 REMARK 1 DOI 10.1038/15674
REMARK 2 REMARK 2 RESOLUTION. 2.20 ANGSTROMS.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.75 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 98.7 REMARK 3 NUMBER OF REFLECTIONS : 70170 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.229 REMARK 3 R VALUE (WORKING SET) : 0.227 REMARK 3 FREE R VALUE : 0.269 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 3715 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 8949 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 233 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 45.11 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.14000 REMARK 3 B22 (A**2) : 0.06000 REMARK 3 B33 (A**2) : 0.08000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.219 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.191 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 14.080 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : NULL ; NULL REMARK 3 ANGLE DISTANCE (A) : NULL ; NULL REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : NULL ; NULL REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4 REMARK 4 1H27 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 06-AUG-02. REMARK 100 THE PDBE ID CODE IS EBI-11185.
REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : NULL REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : NULL REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : NULL REMARK 200 WAVELENGTH OR RANGE (A) : NULL REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : CCP4 (SCALA) REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 63569 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.200 REMARK 200 RESOLUTION RANGE LOW (A) : 28.990 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.7 REMARK 200 DATA REDUNDANCY : 2.600 REMARK 200 R MERGE (I) : 0.07300 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 6.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.32 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.7 REMARK 200 DATA REDUNDANCY IN SHELL : 2.60 REMARK 200 R MERGE FOR SHELL (I) : 0.39900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.400 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 1QMZ REMARK 200 REMARK 200 REMARK: NULL
REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 59.20 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.00 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.8M KCL, 1.2M (NH4)2SO4, 40MM HEPES REMARK 280 PH 7.0. PROTIEN CONCENTRATION = 10MG/ML
REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 36.84350 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 74.04050 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 66.77350 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 74.04050 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 36.84350 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 66.77350 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL
REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA.
REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 400 REMARK 400 COMPOUND REMARK 400 CDK2: CONTROL OF THE CELL CYCLE DURING S PHASE AND G2. REMARK 400 BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES. REMARK 400 REMARK 400 CYCLIN A2: CONTROL OF THE CELL CYCLE. INTERACTS WITH THE CDK2 REMARK 400 AND CDC2 PROTEIN KINASES. REMARK 400 REMARK 400 P27: INVOLVED IN G1 CELL DIVISION PHASE ARREST
REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -4 REMARK 465 PRO A -3 REMARK 465 LEU A -2 REMARK 465 GLY A -1 REMARK 465 LEU A 298 REMARK 465 GLU B 175 REMARK 465 GLY C -4 REMARK 465 PRO C -3 REMARK 465 LEU C -2 REMARK 465 GLY C -1 REMARK 465 SER C 239 REMARK 465 PHE C 240 REMARK 465 PRO C 241 REMARK 465 LYS C 242 REMARK 465 TRP C 243 REMARK 465 LEU C 298 REMARK 465 GLU D 175 REMARK 465 LYS E 25 REMARK 465 PRO E 26 REMARK 465 SER E 27 REMARK 465 ALA E 28 REMARK 465 CYS E 29
REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 297 CA C O CB CG CD NE REMARK 470 ARG A 297 CZ NH1 NH2 REMARK 470 ARG C 297 CA C O CB CG CD NE REMARK 470 ARG C 297 CZ NH1 NH2
REMARK 475 REMARK 475 ZERO OCCUPANCY RESIDUES REMARK 475 THE FOLLOWING RESIDUES WERE MODELED WITH ZERO OCCUPANCY. REMARK 475 THE LOCATION AND PROPERTIES OF THESE RESIDUES MAY NOT REMARK 475 BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 475 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE) REMARK 475 M RES C SSEQI REMARK 475 LYS A 89
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 2018 O HOH A 2019 0.40 REMARK 500 N THR C 39 O HOH C 2012 1.87 REMARK 500 O HOH B 2024 O HOH B 2025 2.03 REMARK 500 N ASP D 284 O HOH D 2021 2.05 REMARK 500 NE2 HIS A 71 NE2 HIS B 296 2.11 REMARK 500 O GLN B 203 O HOH B 2018 2.14 REMARK 500 O TYR D 413 OG SER D 422 2.14 REMARK 500 OE1 GLU A 2 OE2 GLU C 73 2.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 86 CB - CG - OD2 ANGL. DEV. = 5.7 DEGREES REMARK 500 ASP A 256 CB - CG - OD2 ANGL. DEV. = 6.8 DEGREES REMARK 500 ASP A 270 CB - CG - OD2 ANGL. DEV. = 5.8 DEGREES REMARK 500 ASP B 177 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES REMARK 500 ASP B 283 CB - CG - OD2 ANGL. DEV. = 6.1 DEGREES REMARK 500 ASP B 305 CB - CG - OD2 ANGL. DEV. = 7.0 DEGREES REMARK 500 ASP C 68 CB - CG - OD2 ANGL. DEV. = 5.7 DEGREES REMARK 500 ASP C 127 CB - CG - OD2 ANGL. DEV. = 6.1 DEGREES REMARK 500 ASP D 216 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES REMARK 500 ASP D 305 CB - CG - OD2 ANGL. DEV. = 6.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 38 -152.48 58.73 REMARK 500 GLU A 40 -3.75 69.70 REMARK 500 THR A 41 -137.03 -79.92 REMARK 500 LYS A 89 -5.83 -53.27 REMARK 500 SER A 94 54.07 -114.61 REMARK 500 LEU A 96 -72.48 -48.19 REMARK 500 ASP A 127 47.07 -152.89 REMARK 500 ASP A 145 80.10 63.58 REMARK 500 TYR A 159 -169.25 -109.92 REMARK 500 VAL A 164 128.91 83.31 REMARK 500 SER A 181 -145.25 -147.59 REMARK 500 LYS A 291 72.67 -114.96 REMARK 500 HIS A 295 10.40 -65.64 REMARK 500 LEU A 296 162.46 94.10 REMARK 500 TRP B 372 107.22 -30.93 REMARK 500 ASN B 431 71.97 57.43 REMARK 500 GLU C 8 163.12 174.11 REMARK 500 ASP C 38 -70.85 88.08 REMARK 500 THR C 39 167.47 79.36 REMARK 500 GLU C 40 -23.50 74.91 REMARK 500 THR C 41 -102.64 -117.09 REMARK 500 HIS C 84 -70.30 -15.55 REMARK 500 LEU C 96 -72.05 -78.29 REMARK 500 ASP C 127 42.67 -146.48 REMARK 500 ASP C 145 73.87 48.58 REMARK 500 TYR C 159 -165.38 -107.20 REMARK 500 GLU C 162 90.17 -58.45 REMARK 500 VAL C 163 -75.84 -135.35 REMARK 500 SER C 181 -152.88 -160.43 REMARK 500 PRO C 228 101.98 -54.74 REMARK 500 THR C 231 -4.07 -59.03 REMARK 500 ASP C 256 -173.90 -68.54 REMARK 500 PRO D 176 43.32 -61.10 REMARK 500 VAL D 197 -57.34 -16.47 REMARK 500 PRO D 324 -145.14 -84.73 REMARK 500 HIS D 361 -70.92 -65.36 REMARK 500 LEU D 362 -34.04 -39.26 REMARK 500 TYR D 365 0.36 -67.99 REMARK 500 TRP D 372 107.32 -56.27 REMARK 500 TYR D 413 42.12 -89.54 REMARK 500 ASN D 415 157.73 -44.24 REMARK 500 PRO D 427 176.58 -58.27 REMARK 500 ASN D 431 40.97 71.48 REMARK 500 LEU E 32 -95.05 -98.09 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 TPO C 160 13.74 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CHIRAL CENTERS REMARK 500 REMARK 500 UNEXPECTED CONFIGURATION OF THE FOLLOWING CHIRAL REMARK 500 CENTER(S) USING IMPROPER CA--C--CB--N CHIRALITY REMARK 500 FOR AMINO ACIDS AND C1'--O4'--N1(N9)--C2' FOR REMARK 500 NUCLEIC ACIDS OR EQUIVALENT ANGLE REMARK 500 M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,6X,F5.1,6X,A1,10X,A1,3X,A16) REMARK 500 REMARK 500 M RES CSSEQI IMPROPER EXPECTED FOUND DETAILS REMARK 500 VAL C 163 24.9 L L OUTSIDE RANGE REMARK 500 REMARK 500 REMARK: NULL
REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH D2002 DISTANCE = 5.01 ANGSTROMS
REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN E OF CYCLIN-DEPENDENT REMARK 800 KINASE INHIBITOR 1B
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL REMARK 900 CYCLE-REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN REMARK 900 COMPLEX WITH 4-[3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH REMARK 900 THE INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN REMARK 900 COMPLEXED TO HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) REMARK 900 INCOMPLEX WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX REMARK 900 WITH AN OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN REMARK 900 OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) REMARK 900 IN COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE REMARK 900 SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE REMARK 900 INHIBITOR 2-AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO REMARK 900 PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO REMARK 900 PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H06 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO REMARK 900 PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO REMARK 900 PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO REMARK 900 PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0U RELATED DB: PDB REMARK 900 M. SMEGMATIS ARYLAMINE N-ACETYL TRANSFERASE REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED REMARK 900 WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED REMARK 900 WITH THE INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED REMARK 900 WITH THE INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED REMARK 900 WITH THE INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT REMARK 900 PEPTIDE FROM E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 11 RESIDUE RECRUITMENT REMARK 900 PEPTIDE FROM E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 11 RESIDUE RECRUITMENT REMARK 900 PEPTIDE FROM P53 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 11 RESIDUE RECRUITMENT REMARK 900 PEPTIDE FROM P27 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX REMARK 900 WITH 4-[(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) REMARK 900 INCOMPLEX WITH PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H- REMARK 900 INDOL-3-YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{ REMARK 900 4-[2-(7-OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- REMARK 900 YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2- REMARK 900 DIOXIDO-1,3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- REMARK 900 (1,3- OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- REMARK 900 1,2-DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3- REMARK 900 THIAZOL-2- YL)BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO REMARK 900 -2,3- DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
REMARK 999 REMARK 999 SEQUENCE REMARK 999 CHAINS B AND D ARE A TRUNCATED FRAGMENT OF CYCLIN A2 CONSISTING REMARK 999 OF RESIDUES 175-432
DBREF 1H27 A -4 0 PDB 1H27 1H27 -4 0 DBREF 1H27 A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 1H27 B 175 432 UNP P20248 CGA2_HUMAN 175 432 DBREF 1H27 C -4 0 PDB 1H27 1H27 -4 0 DBREF 1H27 C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 1H27 D 175 432 UNP P20248 CGA2_HUMAN 175 432 DBREF 1H27 E 25 35 UNP P46527 CNDB_HUMAN 25 35
SEQRES 1 A 303 GLY PRO LEU GLY SER MET GLU ASN PHE GLN LYS VAL GLU SEQRES 2 A 303 LYS ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA SEQRES 3 A 303 ARG ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS SEQRES 4 A 303 ILE ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR SEQRES 5 A 303 ALA ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS SEQRES 6 A 303 PRO ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU SEQRES 7 A 303 ASN LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP SEQRES 8 A 303 LEU LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE SEQRES 9 A 303 PRO LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU SEQRES 10 A 303 GLN GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS SEQRES 11 A 303 ARG ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU SEQRES 12 A 303 GLY ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA SEQRES 13 A 303 PHE GLY VAL PRO VAL ARG THR TYR TPO HIS GLU VAL VAL SEQRES 14 A 303 THR LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS SEQRES 15 A 303 LYS TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY SEQRES 16 A 303 CYS ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE SEQRES 17 A 303 PRO GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE SEQRES 18 A 303 ARG THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY SEQRES 19 A 303 VAL THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS SEQRES 20 A 303 TRP ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU SEQRES 21 A 303 ASP GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS SEQRES 22 A 303 TYR ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU SEQRES 23 A 303 ALA HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO SEQRES 24 A 303 HIS LEU ARG LEU SEQRES 1 B 259 GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU SEQRES 2 B 259 ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR SEQRES 3 B 259 MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA SEQRES 4 B 259 ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR SEQRES 5 B 259 LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR SEQRES 6 B 259 ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY SEQRES 7 B 259 LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SEQRES 8 B 259 SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU SEQRES 9 B 259 PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN SEQRES 10 B 259 VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR SEQRES 11 B 259 PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR SEQRES 12 B 259 GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL SEQRES 13 B 259 GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE SEQRES 14 B 259 ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE SEQRES 15 B 259 ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR SEQRES 16 B 259 GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY SEQRES 17 B 259 TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU SEQRES 18 B 259 HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SEQRES 19 B 259 SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY SEQRES 20 B 259 VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 C 303 GLY PRO LEU GLY SER MET GLU ASN PHE GLN LYS VAL GLU SEQRES 2 C 303 LYS ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA SEQRES 3 C 303 ARG ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS SEQRES 4 C 303 ILE ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR SEQRES 5 C 303 ALA ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS SEQRES 6 C 303 PRO ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU SEQRES 7 C 303 ASN LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP SEQRES 8 C 303 LEU LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE SEQRES 9 C 303 PRO LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU SEQRES 10 C 303 GLN GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS SEQRES 11 C 303 ARG ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU SEQRES 12 C 303 GLY ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA SEQRES 13 C 303 PHE GLY VAL PRO VAL ARG THR TYR TPO HIS GLU VAL VAL SEQRES 14 C 303 THR LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS SEQRES 15 C 303 LYS TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY SEQRES 16 C 303 CYS ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE SEQRES 17 C 303 PRO GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE SEQRES 18 C 303 ARG THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY SEQRES 19 C 303 VAL THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS SEQRES 20 C 303 TRP ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU SEQRES 21 C 303 ASP GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS SEQRES 22 C 303 TYR ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU SEQRES 23 C 303 ALA HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO SEQRES 24 C 303 HIS LEU ARG LEU SEQRES 1 D 259 GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU SEQRES 2 D 259 ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR SEQRES 3 D 259 MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA SEQRES 4 D 259 ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR SEQRES 5 D 259 LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR SEQRES 6 D 259 ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY SEQRES 7 D 259 LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SEQRES 8 D 259 SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU SEQRES 9 D 259 PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN SEQRES 10 D 259 VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR SEQRES 11 D 259 PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR SEQRES 12 D 259 GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL SEQRES 13 D 259 GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE SEQRES 14 D 259 ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE SEQRES 15 D 259 ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR SEQRES 16 D 259 GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY SEQRES 17 D 259 TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU SEQRES 18 D 259 HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SEQRES 19 D 259 SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY SEQRES 20 D 259 VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 E 11 LYS PRO SER ALA CYS ARG ASN LEU PHE GLY PRO
MODRES 1H27 TPO A 160 THR PHOSPHOTHREONINE MODRES 1H27 TPO C 160 THR PHOSPHOTHREONINE
HET TPO A 160 11 HET TPO C 160 11
HETNAM TPO PHOSPHOTHREONINE
HETSYN TPO PHOSPHONOTHREONINE
FORMUL 1 TPO 2(C4 H10 N O6 P) FORMUL 6 HOH *233(H2 O)
HELIX 1 1 SER A 0 GLU A 2 5 3 HELIX 2 2 PRO A 45 GLU A 57 1 13 HELIX 3 3 LEU A 87 ASP A 92 1 6 HELIX 4 4 PRO A 100 HIS A 121 1 22 HELIX 5 5 LYS A 129 GLN A 131 5 3 HELIX 6 6 ASP A 145 ALA A 149 5 5 HELIX 7 7 THR A 165 ARG A 169 5 5 HELIX 8 8 ALA A 170 LEU A 175 1 6 HELIX 9 9 THR A 182 ARG A 199 1 18 HELIX 10 10 SER A 207 GLY A 220 1 14 HELIX 11 11 GLY A 229 MET A 233 5 5 HELIX 12 12 ASP A 247 VAL A 252 1 6 HELIX 13 13 ASP A 256 LEU A 267 1 12 HELIX 14 14 SER A 276 ALA A 282 1 7 HELIX 15 15 HIS A 283 GLN A 287 5 5 HELIX 16 16 VAL B 175 CYS B 193 1 19 HELIX 17 17 GLY B 198 GLN B 203 5 6 HELIX 18 18 THR B 207 LYS B 226 1 20 HELIX 19 19 GLN B 228 SER B 244 1 17 HELIX 20 20 LEU B 249 GLY B 251 5 3 HELIX 21 21 LYS B 252 GLU B 269 1 18 HELIX 22 22 GLU B 274 THR B 282 1 9 HELIX 23 23 THR B 287 THR B 303 1 17 HELIX 24 24 THR B 310 LEU B 320 1 11 HELIX 25 25 ASN B 326 LEU B 341 1 16 HELIX 26 26 ASP B 343 LEU B 348 1 6 HELIX 27 27 LEU B 351 GLY B 369 1 19 HELIX 28 28 PRO B 373 GLY B 381 1 9 HELIX 29 29 THR B 383 ALA B 401 1 19 HELIX 30 30 PRO B 402 HIS B 404 5 3 HELIX 31 31 GLN B 407 LYS B 414 1 8 HELIX 32 32 ASN B 415 HIS B 419 5 5 HELIX 33 33 GLY B 420 LEU B 424 5 5 HELIX 34 34 PRO C 45 GLU C 57 1 13 HELIX 35 35 LEU C 87 SER C 94 1 8 HELIX 36 36 PRO C 100 HIS C 121 1 22 HELIX 37 37 LYS C 129 GLN C 131 5 3 HELIX 38 38 ASP C 145 ALA C 149 5 5 HELIX 39 39 THR C 165 ARG C 169 5 5 HELIX 40 40 ALA C 170 LEU C 175 1 6 HELIX 41 41 THR C 182 ARG C 199 1 18 HELIX 42 42 SER C 207 GLY C 220 1 14 HELIX 43 43 GLY C 229 MET C 233 5 5 HELIX 44 44 ASP C 247 VAL C 252 1 6 HELIX 45 45 ASP C 256 LEU C 267 1 12 HELIX 46 46 SER C 276 ALA C 282 1 7 HELIX 47 47 HIS C 283 GLN C 287 5 5 HELIX 48 48 TYR D 178 CYS D 193 1 16 HELIX 49 49 GLY D 198 LYS D 202 5 5 HELIX 50 50 THR D 207 LYS D 226 1 20 HELIX 51 51 GLN D 228 MET D 246 1 19 HELIX 52 52 LEU D 249 GLY D 251 5 3 HELIX 53 53 LYS D 252 GLU D 269 1 18 HELIX 54 54 GLU D 274 ILE D 281 1 8 HELIX 55 55 THR D 287 LEU D 302 1 16 HELIX 56 56 THR D 310 PHE D 319 1 10 HELIX 57 57 LEU D 320 GLN D 322 5 3 HELIX 58 58 ASN D 326 ASP D 343 1 18 HELIX 59 59 ASP D 343 LEU D 348 1 6 HELIX 60 60 LEU D 351 THR D 368 1 18 HELIX 61 61 PRO D 373 GLY D 381 1 9 HELIX 62 62 LEU D 387 LYS D 400 1 14 HELIX 63 63 ALA D 401 HIS D 404 5 4 HELIX 64 64 GLN D 407 TYR D 413 1 7 HELIX 65 65 LYS D 414 HIS D 419 5 6 HELIX 66 66 GLY D 420 LEU D 424 5 5
SHEET 1 AA 5 PHE A 4 GLU A 12 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLU C 12 0 SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124
LINK C TYR A 159 N TPO A 160 1555 1555 1.33 LINK C TPO A 160 N HIS A 161 1555 1555 1.37 LINK C TYR C 159 N TPO C 160 1555 1555 1.40 LINK C TPO C 160 N HIS C 161 1555 1555 1.45
CISPEP 1 VAL A 154 PRO A 155 0 -2.10 CISPEP 2 GLN B 323 PRO B 324 0 -11.19 CISPEP 3 ASP B 345 PRO B 346 0 7.30 CISPEP 4 VAL C 154 PRO C 155 0 -6.30 CISPEP 5 GLN D 323 PRO D 324 0 -6.59 CISPEP 6 ASP D 345 PRO D 346 0 12.15
SITE 1 AC1 9 MET B 210 LEU B 214 TRP B 217 GLU B 220 SITE 2 AC1 9 ARG B 250 LEU B 253 GLN B 254 ILE B 281 SITE 3 AC1 9 THR B 285
CRYST1 73.687 133.547 148.081 90.00 90.00 90.00 P 21 21 21 8
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.013571 0.000000 0.000000 0.00000
SCALE2 0.000000 0.007488 0.000000 0.00000
SCALE3 0.000000 0.000000 0.006753 0.00000
MTRIX1 1 0.002810 -0.454650 0.890660 1.38226 1
MTRIX2 1 0.494880 0.774590 0.393840 -60.28027 1
MTRIX3 1 -0.868950 0.439670 0.227180 50.30897 1
MTRIX1 2 0.013340 -0.481640 0.876270 5.61141 1
MTRIX2 2 0.465940 0.778380 0.420750 -61.96182 1
MTRIX3 2 -0.884720 0.402670 0.234800 54.46917 1